Valeant Pharmaceuticals International To Announce 2014 First Quarter Results On May 8, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAVAL, Quebec, April 24, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, May 8, 2014 at 8:00 a.m. ET (5:00 a.m. PT) to discuss results for the 2014 first quarter.

The dial-in number to participate on this call is (877) 876-8393, confirmation code28376511. International callers should dial (973) 200-3961, confirmation code 28376511. A replay will be available approximately two hours following the conclusion of the conference call to Friday, August 8, 2014, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 28376511.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

Valeant Pharmaceuticals International, Inc.

Logo- http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

SOURCE Valeant Pharmaceuticals International, Inc.



Help employers find you! Check out all the jobs and post your resume.

Back to news